AKT1 E17K突变乳腺癌的特征与结局:AACR GENIE登记研究
利用AACR Project GENIE国际临床基因组数据共享联盟,比较153例AKT1 E17K突变与302例AKT1野生型转移性乳腺癌患者的临床结局。AKT1突变组校正后总生存与野生型组相似(中位OS 24.1 vs 29.9,P=0.98),但mTOR抑制剂治疗持续时间更长。研究证明利用公开临床基因组登记数据库定义罕见基因组亚型癌症结局的可行性。
要点
- AKT1 E17K突变转移性乳腺癌校正后OS与野生型相似(中位24.1 vs 29.9,P=0.98)
- AKT1突变患者接受mTOR抑制剂治疗持续时间更长
- 公开临床基因组登记数据库可用于罕见基因组亚型癌症的结局研究
核心结论
- AKT1 E17K突变转移性乳腺癌校正后总生存与AKT1野生型相似,但mTOR抑制剂治疗持续时间更长。
- 利用公开可及的临床基因组登记数据库定义罕见基因组亚型癌症结局是可行的。
研究设计与样本
- 基于AACR Project GENIE国际临床基因组数据共享联盟的 comparative analysis。
- 匹配AKT1 E17K突变转移性乳腺癌153例与AKT1野生型302例。
主要发现
- AKT1突变组校正后总生存与野生型对照组相似(中位OS 24.1 vs 29.9,P=0.98)。
- AKT1突变组mTOR抑制剂治疗持续时间更长,该发现在关键临床试验中因该变异罕见而未被认识。
- 其他基线临床病理特征及其他类别治疗持续时间大致相似。
临床怎么用
- AKT1 E17K突变转移性乳腺癌的自然史与野生型相似,mTOR抑制剂治疗持续时间更长可供临床参考。
- 公开临床基因组登记数据库可用于罕见基因组定义癌症亚型的结局研究,并可能通过合成对照数据辅助药物注册。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AKT inhibitors have promising activity in AKT1 E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinical outcomes of patients with matched AKT1 E17K-mutant (n = 153) and AKT1-wild-type (n = 302) metastatic breast cancer. AKT1-mutant cases had similar adjusted overall survival (OS) compared with AKT1-wild-type controls (median OS, 24.1 vs. 29.9, respectively; P = 0.98). AKT1-mutant cases enjoyed longer durations on mTOR inhibitor therapy, an observation previously unrecognized in pivotal clinical trials due to the rarity of this alteration. Other baseline clinicopathologic features, as well as durations on other classes of therapy, were broadly similar. In summary, we demonstrate the feasibility of using a novel and publicly accessible clincogenomic registry to define outcomes in a rare genomically defined cancer subtype, an approach with broad applicability to precision oncology. SIGNIFICANCE: We delineate the natural history of a rare genomically distinct cancer, AKT1 E17K-mutant ER-positive breast cancer, using a publicly accessible registry of real-world patient data, thereby illustrating the potential to inform drug registration through synthetic control data.See related commentary by Castellanos and Baxi, p. 490.
引用
- Smyth LM, Zhou Q, Nguyen B, et al. Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020. PMID: 31924700. doi:10.1158/2159-8290.CD-19-1209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。